Clinical trials: Amlodipine
Healthy Volunteers
Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules
This study is being performed to determine the bioavailability, or extent of absorption into the body, of a 10 mg amlodipine besylate orally disintegrating tablet (ODT) as compared to the bioavailability of a 10 mg amlodipine…
- Trial name
- NCT01177293
- Testing
- Amlodipine - reference, Amlodipine ODT - test
- Where
- India
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan
- Trial name
- NCT01518998
- Where
- South Korea
- Volunteers
- 420 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension With Hyperlipidemia
Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia
To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia
- Trial name
- NCT03536598
- Testing
- Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg, Amlodipine 10 mg + Valsartan 160 mg, Valsartan 160 mg + Rosuvastatin 20 mg
- Volunteers
- 203 people
- Sponsor
- HK inno.N Corporation
Hypertension
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
To evaluate the blood pressure lowering effect and safety of aliskiren 150 mg used in combination with amlodipine 5 mg in patients with essential hypertension not adequately responsive to amlodipine 5 mg.
- Trial name
- NCT00219076
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 504 people
- Sponsor
- Novartis
Hypertension With Hyperlipidemia
Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia
A Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients with Hyperlipidemia
- Trial name
- NCT03566316
- Testing
- Telmisartan/Amlodipine, Rosuvastatin, Telmisartan
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hypertension
Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years
Primary Objective -To investigate the clinical effectiveness of lacidipine and amlodipine on systolic blood pressure (SBP) in Korean ISH patients aged 60 to 80 years.
- Trial name
- ELDER (NCT00460915)
- Testing
- Lacidipine & Amlodipine
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Korea University Guro Hospital
Hypertension, Left Ventricular Hypertrophy
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH.
- Trial name
- NCT00139555
- Testing
- amlodipine/benazepril
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Novartis
Essential Hypertension
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension
- Trial name
- NCT00157963
- Testing
- MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
- Volunteers
- 174 people
- Sponsor
- Organon and Co
Metabolic Syndrome, Hypertension
Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome
The purpose of this study is to study the effect of two doses of olmesartan medoxomil and amlodipine on vascular markers in hypertensive patients with metabolic syndrome.
- Trial name
- VAMOS (NCT00891267)
- Testing
- Olmesartan medoxomil tablets low dose, Olmesartan medoxomil tablets high dose, Amlodipine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Carotid Artery Stenosis, Strokes
Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes
The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA…
- Trial name
- STANCE (NCT02850081)
- Testing
- Statin, Atorvastatin
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Columbia University
Essential Hypertension
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
CS-8635 combines three widely prescribed antihypertensive medications, olmesartan medoxomil(OM), amlodipine (AML), and hydrochlorothiazide (HCTZ), to lower blood pressure.
- Trial name
- NCT01838850
- Where
- 39 sites in South Korea
- Volunteers
- 344 people
- Sponsor
- Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
Hypertension
Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients
The purpose of this study is to investigate which combination therapy is more effective for improving the blood pressure (BP) and AM central SBP in hypertensive patients:Angiotensin II receptor blocker (ARB) plus calcium channel…
- Trial name
- NCT02294539
- Testing
- Losartan 50mg/amlodipine 5mg, Losartan 100mg/amlodipine 5mg, Losartan 50mg/Hydrochlorothiazide 12.5mg
- Where
- South Korea
- Volunteers
- 231 people
- Sponsor
- Chong-Jin Kim
Hypertension; Hypertrophy, Left Ventricular
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
This study will evaluate the safety and efficacy of amlodipine plus valsartan in patients with hypertension and left ventricular hypertrophy
- Trial name
- NCT00446563
- Testing
- Valsartan, Amlodipine, Hydrochlorothiazide
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Novartis
Hypertension
The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.
The purpose of this study is to compare the effects of the cholesterol medication taken with each blood pressure medication alone on heart disease risk factors including blood pressure, cholesterol, inflammation, blood sugar…
- Trial name
- NCT00656331
- Testing
- Amlodipine and Hydrocholorothiazide
- Where
- United States
- Sponsor
- University of New Mexico
Angina
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain…
- Trial name
- NCT00091429
- Testing
- Ranolazine
- Volunteers
- 500 people
- Sponsor
- Gilead Sciences
Hypertension
Amlodipine Prevents Morning Blood Pressure Surge Study
1. Study name:Amlodipine Prevents Morning Blood Pressure Surge Study 2. Study drugs:amlodipine (Norvasc®) and nifedipine GITS (Adalat®) 3.
- Trial name
- ARMORS (NCT01030081)
- Testing
- Amlodipine (Norvasc®), Nifedipine GITS (Adalat® XL 30
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Primary Hypertension
Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients
The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) is a 2-arm, multi-center, prospective, randomized, open-labeled, blinded-endpoint trial.
- Trial name
- STEP (NCT03015311)
- Testing
- Intensive BP control, Standard BP control
- Where
- 42 sites in China
- Volunteers
- 8,000 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Hypertension
Clinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With Hypertension
Hypertension is closely related to metabolic abnormalities such as obesity, dyslipidemia and diabetes. When hypertension is complicated with metabolic abnormalities, target organ damage is more serious, the risk of cardiovascular…
- Trial name
- NCT03956823
- Testing
- telmisartan, amlodipine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hypertension
Telmisartan 80mg Non-responder Trial
If a patient cannot have his or her blood pressure controlled with telmisartan 80 mg, an antihypertensive drug from different class should be started concomitantly.
- Trial name
- NCT01222520
- Testing
- Telmisartan and amlodipine, Telmisartan
- Where
- 4 sites in Japan
- Volunteers
- 174 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Hypertension Resistant to Conventional Therapy
Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)
The ANDORRA study is a, multicenter, prospective, open, randomized, controlled blinded endpoint trial (PROBE) comparing two treatment strategies (renal artery stenting + standardized and optimized medical treatment [SOMT] versus…
- Conditions
- Hypertension, Hypertension Resistant to Conventional Therapy, Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent
- Trial name
- ANDORRA (NCT02539810)
- Testing
- Renal artery Angioplasty plus stenting., Anti hypertensive, statin and antiplatelet medication.
- Where
- 15 sites in France
- Volunteers
- 4 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris